

## **Product Description**

Pioneering GTPase and Oncogene Product Development since 2010

## **HUMAN IL-12 PROTEIN**

目录: 12248

产品名称: Human IL-12 Protein 规格: 10 μg, 50 μg and 100 μg

基因符号: Interleukin-12 subunit alpha;IL-12A;Cytotoxic lymphocyte

maturation factor 35 kDa subunit;CLMF p35;IL-12 subunit p35;NK cell;IL12A

;NKSF1 stimulatory factor chain 1

Target: IL-12

**UNIPROT ID:** P29459;P29460

描述: Recombinant Human Interleukin-12 is produced by our Mammalian expression system and the target gene encoding Arg23-Ser219andIle23-Ser328 is expressed.

背景: IL-12 is a heterodimeric pleiotropic cytokine made up of a 40 kDa (p40) subunit and a 35 kDa (p35) subunit. Human and mouse IL?12 share 70% and 60% amino acid sequence identity in their p40 and p35 subunits, respectively. IL-12 is involved in the differentiation of naive T cells into Th1 cells. It is known as a T cell-stimulating factor, which can stimulate the growth and function of T cells. It stimulates the production of interferongamma (IFN-γ) and tumor necrosis factor-alpha (TNF-a) from T cells and natural killer (NK) cells, and reduces IL-4 mediated suppression of IFN-γ. T cells that produce IL-12 have a coreceptor, CD30, which is associated with IL-12 activity.IL-12 plays an important role in the activities of natural killer cells and T lymphocytes. IL-12 mediates enhancement of the cytotoxic activity of NK cells and CD8 cytotoxic T lymphocytes.

Species/Host: HEK293

Molecular Weight: 22.5and34.7 KDa

Molecular Characterization: Not available

纯化:: Greater than 95% as determined by reducing SDS-PAGE.

**Formulation & Reconstitution:** Lyophilized from nanodisc solubilization buffer (20 mM Tris-HCl, 150 mM NaCl, pH 8.0). Normally 5% – 8% trehalose is added as protectants before lyophilization.

储存和运输: Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). Lyophilized proteins are shipped at ambient temperature.



## **Product Description**

Pioneering GTPase and Oncogene Product Development since 2010




Figure 1. Greater than 95% as determined by reducing SDS-PAGE.